Swedish drug development pipeline 2013
| Reference number | |
| Coordinator | SwedenBIO Service AB |
| Funding from Vinnova | SEK 100 000 |
| Project duration | December 2012 - June 2013 |
| Status | Completed |
Purpose and goal
The aim was to identify the project portfolio ´pipeline´ of new drugs in Swedish companies with R&D activities in Sweden and thus visualize the state of the industry and the need for support. The goal was to get a clear idea of the situation with respect to projects that have reached the clinic (Phase I-III), and the number of drugs that were approved during the past year. The survey was conducted during the first half at 2013 and was compiled in the fall. The report was presented at Sweden Bio´s CEO Summit on December 2. The project is considered to be implemented.
Results and expected effects
A report was compiled according to plan and has attracted attention in the media and presented at industry meetings. The result was presented at a Nordic meeting ´Meeting clinical studies´ in Oslo and it is mentioned in the report of the investigation for national coordination of clinical trials: Starka tillsammans, SOU 2013:87.
Approach and implementation
Initially, research was done in order to identify Swedish pharmaceutical- and biotech companies. The companies were then invited to fill in an online questionnaire with questions about their projects. The online survey was redesigned and developed for this year´s report. Our view is that the revision had the desired outcome. About one hundred companies were identified.